ScoreWhy is Dizal (Jiangsu) Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 18.72%
- The company has been able to generate a Return on Capital Employed (avg) of 18.72% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 149.43% and Operating profit at -254.66% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has reported losses. Due to this company has reported negative ROE
3
Poor long term growth as Net Sales has grown by an annual rate of 149.43% and Operating profit at -254.66% over the last 5 years
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 0.11%, its profits have risen by 13.2%
5
Underperformed the market in the last 1 year
- The stock has generated a return of 0.11% in the last 1 year, much lower than market (China Shanghai Composite) returns of 22.49%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Dizal (Jiangsu) Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Miscellaneous should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Dizal (Jiangsu) Pharmaceutical Co., Ltd. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
-38.93%
0.39
51.05%
China Shanghai Composite
16.78%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
233.93%
EBIT Growth (5y)
-323.72%
EBIT to Interest (avg)
-7.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
27.08
Sales to Capital Employed (avg)
0.24
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.72%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
13.86
EV to EBIT
-23.22
EV to EBITDA
-25.27
EV to Capital Employed
22.84
EV to Sales
18.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-98.37%
ROE (Latest)
-56.70%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
OPERATING PROFIT MARGIN(Q)
Highest at -41.83 %
RAW MATERIAL COST(Y)
Fallen by -13.77% (YoY
NET SALES(Q)
Highest at CNY 252.52 MM
OPERATING PROFIT(Q)
Highest at CNY -105.64 MM
PRE-TAX PROFIT(Q)
Highest at CNY -103.1 MM
NET PROFIT(Q)
Highest at CNY -102.31 MM
EPS(Q)
Highest at CNY -0.21
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Net Sales
At CNY 252.52 MM has Grown at 58.18%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CNY MM)
Operating Profit Margin
Highest at -41.83 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Sales
Highest at CNY 252.52 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY -105.64 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Pre-Tax Profit
Highest at CNY -103.1 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY -102.31 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY -0.21
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Raw Material Cost
Fallen by -13.77% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
